ArriVent BioPharma
All
Newsflash
Article
-
ArriVent BioPharma's shares plummeted nearly 47% after its China-licensed cancer drug failed a late-stage trial.
Shares of U.S. biopharmaceutical company ArriVent BioPharma plummeted nearly 47% on Tuesday after it reported that firmonertinib, a cancer treatment licensed from Shanghai Allist Pharmaceuticals in Ch
-
ArriVent BioPharma's shares plummeted nearly 47% after its China-licensed cancer drug failed a late-stage trial.
Shares of U.S. biopharmaceutical company ArriVent BioPharma plummeted nearly 47% on Tuesday after it reported that firmonertinib, a cancer treatment licensed from Shanghai Allist Pharmaceuticals in Ch
- No data
ArriVent BioPharma
Svmuu provides news and information related to ArriVent BioPharma, as well as real-time data on ArriVent BioPharma. We provide in-depth analysis and interpretation of the latest ArriVent BioPharma developments, helping investors stay informed about ArriVent BioPharma policy updates. Svmuu is your essential tool for keeping up with the latest ArriVent BioPharma trends! Here, we’ll join you in keeping a close eye on ArriVent BioPharma news and use a clear macro perspective to make sense of the uncertain future of crypto.
24H Trending
-
1
Amazon fell 4.1% from its previous close, currently trading at $246.820.
-
2
Palantir closed down 6.63% from its previous close, currently trading at $143.490.
-
3
The Russell 2000 Index fell 2.76% from its previous close, currently trading at 2,581.79.
-
4
Silver prices pulled back to $41.103, touching a nearly 365-day low
-
5
Oracle is down 8.48% from its previous close, currently trading at $101.190.
-
6
Coinbase closed down 6.34% from its previous session, currently trading at $101.970.
-
7
MicroStrategy was down 9.67% from its previous close, currently trading at $77.80.
-
8
Gold fell 3.64% from its previous close, currently trading at $3,533.24.
-
9
Tesla closed 7.64% lower, currently trading at $345.820.
-
10
Gold prices retreated to $3,533.24, hitting a nearly 365-day low.
Markets Today
Recommended Reading
